2/9
04:46 pm
vir
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Neutral
Report
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
2/9
04:05 pm
vir
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
Neutral
Report
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
2/9
08:04 am
vir
Vir Biotechnology (NASDAQ:VIR) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.
2/5
09:30 pm
vir
Vir Biotechnology: The Low-Down On The Readouts Ahead [Seeking Alpha]
Medium
Report
Vir Biotechnology: The Low-Down On The Readouts Ahead [Seeking Alpha]
2/4
06:09 am
vir
Vir Biotechnology (NASDAQ:VIR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
1/12
08:32 am
vir
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones [Yahoo! Finance]
Low
Report
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones [Yahoo! Finance]
1/12
08:00 am
vir
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
Low
Report
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
1/5
04:05 pm
vir
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/30
08:42 am
vir
Vir Biotechnology (NASDAQ:VIR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
12/17
03:27 am
vir
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology [Yahoo! Finance]
Medium
Report
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology [Yahoo! Finance]
12/16
04:42 pm
vir
Vir Biotechnology (NASDAQ:VIR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Vir Biotechnology (NASDAQ:VIR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/16
04:36 pm
vir
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program [Yahoo! Finance]
Medium
Report
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program [Yahoo! Finance]
12/16
04:05 pm
vir
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
Medium
Report
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
12/2
03:47 pm
vir
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
01:59 pm
vir
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
04:05 pm
vir
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
Low
Report
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
11/18
10:50 am
vir
Global Leaders Driving The Future Of Healthcare At The 2025 Forbes Healthcare Summit [Forbes]
Low
Report
Global Leaders Driving The Future Of Healthcare At The 2025 Forbes Healthcare Summit [Forbes]